nach oben

European Journal of Nuclear Medicine and Molecular Imaging

07.05.2024 | Editorial

Collection on molecular imaging in cardiac amyloidosis

verfasst von: Federico Caobelli, Christoph Rischpler

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Excerpt

Cardiac amyloidosis (CA) is a complex and often underdiagnosed pathological condition, which poses significant challenges in both its detection and management. As the efficacy of the currently approved therapy decreases over time and is lowest in the advanced stages of the disease, a prompt diagnosis is mandatory to yield favourable outcome [1]. In this context, there is the need for reliable imaging modalities able to provide with an early and accurate diagnosis, along with useful prognostic information [2]. …

Caobelli F. Recent evidence on Cardiac 99mTc-DPD Uptake after Therapy with Tafamidis May reveal the Road to an Ultra-early diagnosis in patients with ATTR Amyloidosis. J Nucl Med. 2024;65:329.CrossRefPubMed

Abadie B, Ali AH, Martyn T, Higgins A, Krishnaswamy A, Reed G, Puri R, Yun J, Cremer P, Hanna M, Tang WHW, Kapadia S, Jaber W. Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR. Eur J Nucl Med Mol Imaging. 2023;50:3910–6.CrossRefPubMed

Gotuzzo I, Slart RHJA, Gimelli A, Ashri N, Anagnostopoulos C, Bucerius J, Buechel RR, Gaemperli O, Gheysens O, Glaudemans AWJM, Habib G, Hyafil F, Lubberink M, Saraste A, Podlesnikar T, Dweck MR, Erba PA. Nuclear medicine practice for the assessment of cardiac sarcoidosis and amyloidosis. A survey endorsed by the EANM and EACVI. Eur J Nucl Med Mol Imaging. 2024 Apr;29. https://doi.org/10.1007/s00259-024-06727-5. Epub ahead of print.

Tingen HSA, Tubben A, van ‘t Oever JH, Pastoor EM, van Zon PPA, Nienhuis HLA, van der Meer P, Slart RHJA. Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review. Eur J Nucl Med Mol Imaging. 2023;51:93–109.CrossRefPubMedPubMedCentral

Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative [99mTc]Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27:1456–63.CrossRefPubMed

Rettl R, Calabretta R, Duca F et al. Reduction in [99mTc]Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy. Amyloid. 2023:1–10.

Rettl R, Wollenweber T, Duca F, et al. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24:1019–30.CrossRefPubMedPubMedCentral

Papathanasiou M, Kessler L, Bengel FM, et al. Regression of myocardial [99mTc]Tc-DPD uptake after Tafamidis Treatment of Cardiac Transthyretin Amyloidosis. J Nucl Med. 2023;64:1083–6.CrossRefPubMed

Tingen HSA, Tubben A, Bijzet J, van den Berg MP, van der Meer P, Houwerzijl EJ, Muntinghe FLH, van der Zwaag PA, Glaudemans AWJM, Oerlemans MIFJ, Knackstedt C, Michels M, Hirsch A, Hazenberg BPC, Slart RHJA, Nienhuis HLA. Cardiac [^99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? Eur J Nucl Med Mol Imaging. 2024;51:681–90.CrossRefPubMed

10.

Gheysens O, Treglia G, Masri A, Hyafil F, Dorbala S. Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals? Eur J Nucl Med Mol Imaging. 2024;51:691–4.CrossRefPubMed

11.

Rischpler C, Kersting D, Kessler L, Varasteh Z, Luedike P, Carpinteiro A, Rassaf T, Herrmann K, Papathanasiou M, Reply. Recent evidence on Cardiac 99mTc-DPD Uptake after Therapy with Tafamidis May reveal the Road to an Ultra-early diagnosis in patients with ATTR Amyloidosis. J Nucl Med. 2024;65:330.CrossRefPubMed

12.

Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, Schrutka L, Dalos D, Koschutnik M, Donà C, Kammerlander A, Beitzke D, Loewe C, Charwat-Resl S, Hengstenberg C, Kastner J, Eslam RB, Bonderman D. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:767–80.CrossRefPubMed

13.

Wang X, Guo Y, Gao Y, Ren C, Huang Z, Liu B, Li X, Chang L, Shen K, Ding H, Zhang H, Tian Z, Hacker M, Zhang S, Wang Y, Li J, Li X, Huo L. Feasibility of 68Ga-Labeled fibroblast activation protein inhibitor PET/CT in Light-Chain Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022;15:1960–70.CrossRefPubMed

14.

Clerc OF, Cuddy SAM, Robertson M, Vijayakumar S, Neri JC, Chemburkar V, Kijewski MF, Di Carli MF, Bianchi G, Falk RH, Dorbala S. Cardiac amyloid quantification using 124I-Evuzamitide (124I-P5 + 14) Versus 18F-Florbetapir: a pilot PET/CT study. JACC Cardiovasc Imaging. 2023;16:1419–32.CrossRefPubMedPubMedCentral

Titel: Collection on molecular imaging in cardiac amyloidosis
verfasst von: Federico Caobelli
Christoph Rischpler
Publikationsdatum: 07.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06739-1

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Collection on molecular imaging in cardiac amyloidosis

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten